Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Sponsor: National Cancer Institute (NCI)
A PHASE3 clinical study on Prostate Cancer, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 13 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Dec 2021 — Jul 2022 [monthly]
Unknown Status PHASE3
▶ Show 8 earlier versions
-
Oct 2021 — Dec 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
Jul 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jul 2019 [monthly]
Active Not Recruiting PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Apr 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Feb 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
For direct contact, visit the study record on ClinicalTrials.gov .